Literature DB >> 15297501

Verification of an assay for quantification of hepatitis C virus RNA by use of an analyte-specific reagent and two different extraction methods.

Michael S Forman1, Alexandra Valsamakis.   

Abstract

Protocols were designed for quantification and detection of hepatitis C virus (HCV) RNA by the use of an analyte-specific reagent (ASR) (Roche COBAS TaqMan48 [CTM48] HCV) after manual and automated RNA extraction. The purposes were to determine (i) assay performance characteristics using manual and automated RNA extraction methods, (ii) whether measurable range and limit of detection (LOD) of the ASR assay were influenced by genotype, and (iii) correlation of quantification by CTM48 HCV ASR and COBAS Monitor HCV v. 2.0. For HCV genotype 1 (Gt1), the lower limits of quantification after manual extraction were slightly lower than those for automated extraction (1.0 versus 1.5 log(10) IU/ml). Results were linear up to the highest concentration tested after extraction by both methods (manual, 6.1 log(10); automated, 6.4 log(10)). Similar results were obtained for Gt2 (1.8 to 6.8 log(10) IU/ml) and Gt3 (1.6 to 6.8 log(10) IU/ml) after automated extraction. The LOD of Gt1 virus was 10 IU/ml after manual extraction and between 25 and 37.5 IU/ml after automated extraction. Results with Gt2 and Gt3 viruses were similar after automated extraction (Gt2, between 25 and 50 IU/ml; Gt3, 25 IU/ml). Variability (intrarun and interrun, at concentrations throughout the range of quantification) was </=13% for both extraction methods. Clinical specimens tested by Monitor were quantified using the CTM48 HCV ASR assay. Characteristics of the regression line included a slope of 0.98 and y intercept of -0.23. Quantification by the two methods was correlated (r = 0.97). CTM48 HCV ASR assay values were on average twofold lower than those for Monitor HCV v. 2.0. These data suggest that our assay combines the characteristics of qualitative and quantitative PCR platforms into a single test.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15297501      PMCID: PMC497620          DOI: 10.1128/JCM.42.8.3581-3588.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  7 in total

1.  Hepatitis C virus subtyping by a core-envelope 1-based reverse transcriptase PCR assay with sequencing and its use in determining subtype distribution among Danish patients.

Authors:  Sylvie Corbet; Jens Bukh; Anja Heinsen; Anders Fomsgaard
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

2.  Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays.

Authors:  J Mellor; A Hawkins; P Simmonds
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

3.  Overestimation of the hepatitis C virus RNA content of reference preparations by the AMPLICOR HCV monitor test, version 2.0.

Authors:  Giulio Pisani; Karen Cristiano; Maria Wirz; Guillermo M Bisso; Giuliano Gentili
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

4.  Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics.

Authors:  S C Lee; A Antony; N Lee; J Leibow; J Q Yang; S Soviero; K Gutekunst; M Rosenstraus
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

5.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

6.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

7.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Authors:  Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391

  7 in total
  14 in total

1.  Multicenter trials need to use the same assay for hepatitis C virus viral load determination.

Authors:  Syria Laperche; Françoise Bouchardeau; Vincent Thibault; Bruno Pozzetto; Sophie Vallet; Arielle R Rosenberg; Anne-Marie Roque-Afonso; Michèle Gassin; Françoise Stoll-Keller; Pascale Trimoulet; Elyanne Gault; Bruno Chanzy; Bernard Mercier; Michel Branger; Jean-Michel Pawlotsky; Cécile Henquell; Françoise Lunel; Catherine Gaudy-Graffin; Sophie Alain; Marie-Laure Chaix; Gilles Duverlie; Jacques Izopet; Jean-Jacques Lefrère
Journal:  J Clin Microbiol       Date:  2007-10-03       Impact factor: 5.948

2.  Automated extraction of viral-pathogen RNA and DNA for high-throughput quantitative real-time PCR.

Authors:  Kurt Beuselinck; Marc van Ranst; J van Eldere
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

3.  Interpretation of real-time PCR results for hepatitis C virus RNA when viral load is below quantification limits.

Authors:  Syria Laperche; Françoise Bouchardeau; Elisabeth André-Garnier; Vincent Thibault; Anne-Marie Roque-Afonso; Pascale Trimoulet; Ronald Colimon; Gilles Duverlie; Hélène Leguillou-Guillemette; Françoise Lunel; Magali Bouvier-Alias; Jean-Michel Pawlotsky; Cécile Henquell; Evelyne Schvoerer; Françoise Stoll-Keller; Marie-Laure Chaix; Michel Branger; Catherine Gaudy-Graffin; Arielle R Rosenberg; Bruno Pozzetto; Sophie Vallet; Yazid Baazia; Jacques Izopet; Jean-Jacques Lefrère
Journal:  J Clin Microbiol       Date:  2011-01-12       Impact factor: 5.948

4.  Broad differences between the COBAS ampliprep total nucleic acid isolation-COBAS TaqMan 48 hepatitis C virus (HCV) and COBAS HCV monitor v2.0 assays for quantification of serum HCV RNA of non-1 genotypes.

Authors:  Philippe Colson; Anne Motte; Catherine Tamalet
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

5.  Multilaboratory comparison of hepatitis C virus viral load assays.

Authors:  A M Caliendo; A Valsamakis; Y Zhou; B Yen-Lieberman; J Andersen; S Young; A Ferreira-Gonzalez; G J Tsongalis; R Pyles; J W Bremer; N S Lurain
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

6.  The role of human metapneumovirus in upper respiratory tract infections in children: a 20-year experience.

Authors:  John V Williams; Chiaoyin K Wang; Chin-Fen Yang; Sharon J Tollefson; Frances S House; Josh M Heck; Marla Chu; Jennifer B Brown; Linda D Lintao; Joe D Quinto; David Chu; Richard R Spaete; Kathryn M Edwards; Peter F Wright; James E Crowe
Journal:  J Infect Dis       Date:  2005-12-30       Impact factor: 5.226

7.  Performance characteristics of a quantitative hepatitis C virus RNA assay using COBAS AmpliPrep total nucleic acid isolation and COBAS taqman hepatitis C virus analyte-specific reagent.

Authors:  Michael S Forman; Alexandra Valsamakis
Journal:  J Mol Diagn       Date:  2008-02-14       Impact factor: 5.568

8.  Detection and quantification of hepatitis C virus (HCV) by MultiCode-RTx real-time PCR targeting the HCV 3' untranslated region.

Authors:  Elizabeth K Mulligan; J J Germer; Max Q Arens; Krista L D'Amore; Adrian Di Bisceglie; Nathan A Ledeboer; Michael J Moser; Andrew C Newman; Andy K O'Guin; Paul D Olivo; Diane S Podzorski; Kimberly A Vaughan; Joseph D Yao; Slava A Elagin; Scott C Johnson
Journal:  J Clin Microbiol       Date:  2009-06-17       Impact factor: 5.948

9.  Anomalous quantitation standard growth curves in a laboratory-developed hepatitis C virus (HCV) RNA quantification assay using the TaqMan HCV analyte-specific reagent.

Authors:  Jeffrey J Germer; Jemee D Kathrotiya; Carrie F Bouse; P Shawn Mitchell; Joseph D C Yao
Journal:  J Clin Microbiol       Date:  2009-05-06       Impact factor: 5.948

10.  Comparison of performance characteristics of three real-time reverse transcription-PCR test systems for detection and quantification of hepatitis C virus.

Authors:  M Fernanda Sábato; Mitchell L Shiffman; Michael R Langley; David S Wilkinson; Andrea Ferreira-Gonzalez
Journal:  J Clin Microbiol       Date:  2007-06-13       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.